Compare Neurocrine Biosciences Inc (NBIX) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Plug Power Inc — how do they compare? Neurocrine Biosciences Inc trades at $162.07 (market cap $16.76B), while Plug Power Inc trades at $2.23 (market cap $2.94B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.7× Plug Power Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | PLUG | |
|---|---|---|
Market Cap | $16.76B | $2.94B |
Sector | Health | Industrials |
52-Week High | $185.50 | $4.14 |
52-Week Low | $123.10 | $1.41 |
Enterprise Value | $16.78B | $3.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Plug Power (PLUG) trades at $2.18, up 5.31% with a bearish technical signal despite recent earnings beat. The company shows improving operational metrics with reduced cash usage and margin improvements, though it remains unprofitable with negative gross margins of -25.66%. Management targets positive EBITDA by Q4 2026 while navigating significant liquidity challenges through asset sales and financing activities.
While analyst consensus leans bullish with a $2.22 price target, PLUG faces substantial execution risks amid persistent losses and cash burn. The stock offers speculative upside if management delivers on profitability targets, but investors face elevated risk from the company's negative cash flow and competitive hydrogen market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
